Endoscopic Lung Volume Reduction: Review of the EMPROVE and LIBERATE trials

Khaled M. Nada; Shawn Nishi

doi:10.1016/j.mayocpiqo.2020.09.009

Endoscopic Lung Volume Reduction: Review of the EMPROVE and LIBERATE trials

Khaled M. Nada
, Shawn Nishi

Internal Medicine

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Abstract

Endoscopic lung volume reduction is now included in the guidelines for treatment in severe chronic obstructive pulmonary disease. Since December 2018, 2 valve systems have been approved by the US Food and Drug Administration (FDA). To date, there is no head-to-head trial comparing both valve systems and no clear benefit of one over the other. This article provides an overview of the two largest prospective trials performed with the FDA-approved valve systems.

Original language	English (US)
Pages (from-to)	177-186
Number of pages	10
Journal	Mayo Clinic Proceedings: Innovations, Quality and Outcomes
Volume	5
Issue number	1
DOIs	https://doi.org/10.1016/j.mayocpiqo.2020.09.009
State	Published - Feb 2021

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/j.mayocpiqo.2020.09.009

Cite this

@article{752bfd123ec746838b39a14ebe3a2828,

title = "Endoscopic Lung Volume Reduction: Review of the EMPROVE and LIBERATE trials",

abstract = "Endoscopic lung volume reduction is now included in the guidelines for treatment in severe chronic obstructive pulmonary disease. Since December 2018, 2 valve systems have been approved by the US Food and Drug Administration (FDA). To date, there is no head-to-head trial comparing both valve systems and no clear benefit of one over the other. This article provides an overview of the two largest prospective trials performed with the FDA-approved valve systems.",

author = "Nada, \{Khaled M.\} and Shawn Nishi",

note = "Publisher Copyright: {\textcopyright} 2020 Mayo Foundation for Medical Education and Research",

year = "2021",

month = feb,

doi = "10.1016/j.mayocpiqo.2020.09.009",

language = "English (US)",

volume = "5",

pages = "177--186",

journal = "Mayo Clinic Proceedings: Innovations, Quality and Outcomes",

issn = "2542-4548",

publisher = "Elsevier B.V.",

number = "1",

}

TY - JOUR

T1 - Endoscopic Lung Volume Reduction

T2 - Review of the EMPROVE and LIBERATE trials

AU - Nada, Khaled M.

AU - Nishi, Shawn

PY - 2021/2

Y1 - 2021/2

N2 - Endoscopic lung volume reduction is now included in the guidelines for treatment in severe chronic obstructive pulmonary disease. Since December 2018, 2 valve systems have been approved by the US Food and Drug Administration (FDA). To date, there is no head-to-head trial comparing both valve systems and no clear benefit of one over the other. This article provides an overview of the two largest prospective trials performed with the FDA-approved valve systems.

AB - Endoscopic lung volume reduction is now included in the guidelines for treatment in severe chronic obstructive pulmonary disease. Since December 2018, 2 valve systems have been approved by the US Food and Drug Administration (FDA). To date, there is no head-to-head trial comparing both valve systems and no clear benefit of one over the other. This article provides an overview of the two largest prospective trials performed with the FDA-approved valve systems.

UR - https://www.scopus.com/pages/publications/85164061499

UR - https://www.scopus.com/pages/publications/85164061499#tab=citedBy

U2 - 10.1016/j.mayocpiqo.2020.09.009

DO - 10.1016/j.mayocpiqo.2020.09.009

M3 - Review article

AN - SCOPUS:85164061499

SN - 2542-4548

VL - 5

SP - 177

EP - 186

JO - Mayo Clinic Proceedings: Innovations, Quality and Outcomes

JF - Mayo Clinic Proceedings: Innovations, Quality and Outcomes

IS - 1

ER -

Endoscopic Lung Volume Reduction: Review of the EMPROVE and LIBERATE trials

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this